Arrowhead initiates patients dosing in Phase IIa trial of ARC-520 to treat chronic hepatitis B
Around 16 chronic HBV patients will be enrolled in multi-center, randomized, double-blind, placebo-controlled, dose-escalation Phase IIa trial, which is being conducted at Queen Mary Hospital and Prince of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.